Drug Safety Oversight Board Meeting, April 16, 2009

Public Summary

• The Executive Director updated the Board on risk communications [Public Health Advisories (PHAs), Early Communications about Ongoing Safety Reviews (ECs) and Information for Healthcare Professionals (HCP)] posted and currently in development since the February 19, 2009 meeting (all available at: Index to Drug-Specific Information).
• The Drug Safety Oversight Board (DSB) discussed two topics: the product orlistat and the potential risk of hepatotoxicity and alcohol-based skin antiseptics and the risk of a fire in the operating room.